You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Non-Diabetic Nephropathy - Use of ACE Inhibitor or ARB Therapy

The percentage of patients aged 18 years and older with proteinuria who are taking an ACE inhibitor or ARB

Date Reviewed: November 23, 2013

Measure Info

NQF 0621NQF Endorsement Removed
Measure Type: 
Process
Measure Steward: 
ActiveHealth Management
Clinical Topic Area: 
Chronic Kidney Disease

Care Setting: 
Outpatient
Data Source: 
Claims
Electronic Health Records
Instrument-Based Data

ACP does not support NQF 0621: “Non-Diabetic Nephropathy - Use of ACE Inhibitor or ARB Therapy.” While the clinical reasoning underlying the measure is sound, it does not reflect the most recent Kidney Disease | Improving Global Outcomes (KDIGO) guidelines on the management of CKD. Cut-points in the denominator and exclusion criteria should be updated to align with current recommended practice standards. Specifically, KDIGO recommends an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) for diabetic CKD patients with albumin excretion of 30-300 mg/24 hours, and for patients with albumin excretion greater than 300 mg/24 hours, regardless of diabetes status. The division of stage 3 CKD into stages 3a (GFR 45-59 ml/min/1.73 m2) and 3b (GFR 30-44 ml/min/1.73 m2) should also be noted explicitly in the exclusion criteria along with guidance as to whether both patient populations should be excluded.